Press Releases

Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System Redwood City, Calif. – August 20, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions

Redwood City, CA – August 17, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales.  Mr. Whistance

More Than 50 Million Covered Lives Added in First 6 Months of 2020 Redwood City, CA, July 20, 2020 — Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that health insurance coverage of more than 50

Sonata Demonstrates Significant Advantages in Reducing Procedure Time, Length of Stay and Procedure Related Costs Compared to Myomectomy Redwood City, CA, June 30, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine

Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing Redwood City, CA – June 22, 2020 - Gynesonics®, a women’s healthcare company focused on the

The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of

EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine